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Abstract 
Objective: To investigate the relationship among body mass index (BMI), cardiometabolic risk and coronary artery 
disease (CAD) among patients undergoing coronary computed tomography angiography (CTA).
Methods: Retrospective cohort study of 1118 patients, who underwent coronary CTA at two centers from Septem-
ber 2004 to October 2011. Coronary CTA were categorized as normal, nonobstructive CAD (<50%), or obstructive CAD 
(≥50%) in addition to segment involvement (SIS) and stenosis scores. Extensive CAD was defined as SIS > 4. Associa-
tion of BMI with cardiovascular prognosis was evaluated using multivariable fractional polynomial models.
Results: Mean age of the cohort was 57 ± 13 years with median follow-up of 3.2 years. Increasing BMI was associ-
ated with MetS (OR 1.28 per 1 kg/m2, p < 0.001) and burden of CAD on a univariable basis, but not after multivariable 
adjustment. Prognosis demonstrated a J-shaped relationship with BMI. For BMI from 20–39.9 kg/m2, after adjustment 
for age, gender, and smoking, MetS (HR 2.23, p = 0.009) was more strongly associated with adverse events.
Conclusions: Compared to normal BMI, there was an increased burden of CAD for BMI > 25 kg/m2. Within each BMI 
category, metabolically unhealthy patients had greater extent of CAD, as measured by CCTA, compared to metaboli-
cally healthy patients.
Keywords: Obesity, Metabolic syndrome, Coronary computed tomography angiography, Coronary artery disease, 
Prognosis, Cohort
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Background
Atherosclerosis, obesity, metabolic syndrome (MetS), and 
diabetes mellitus are closely linked and constitute major 
health problems worldwide. Not only has the prevalence 
of obesity been increasing to epidemic proportions in the 
United States, but obesity is also causally related to most 
of the major cardiovascular (CV) risk factors, including 
high blood pressure, dyslipidemia and insulin resistance 
leading to metabolic syndrome and type-2 diabetes mel-
litus [1]. Due to accelerated systemic atherosclerosis and 
resultant high cardiovascular event rates among patients 
with type-2 diabetes, the World Health Organization 
has called for increased preventive efforts to stem the 
tide of increasing prevalence of type-2 diabetes, which 
occurs in association with obesity [2]. Beyond risk factor 
changes, obesity also increases the risk of future cardio-
vascular events. Nevertheless, some research has pointed 
out that certain groups of obese patients may fare bet-
ter, the so-called “obesity paradox” [3], and likewise have 
questioned the importance of obesity without metabolic 
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abnormalities (“metabolically healthy obesity”) on the 
development of future adverse CV events [1].
The metabolic syndrome has been used to identify indi-
viduals who have a cluster of risk factors, which together 
pose a higher prevalence of CAD and increased risk of 
subsequent clinical cardiovascular disease (CVD). The 
increased CVD risk appears to be related to the risk factor 
clustering and insulin resistance associated with the meta-
bolic syndrome rather than simply to obesity [4–7]. More-
over, individuals with MetS have a higher risk of CAD 
when coronary artery calcium (CAC) is increased [8].
The independent association between obesity and car-
diovascular disease, particularly coronary artery disease 
remains controversial. A recent meta-analysis found that 
compared with metabolically healthy normal-weight 
individuals, obese individuals are at increased risk for 
adverse long-term CVD events even in the absence of 
metabolic abnormalities, suggesting that there is no 
healthy pattern of increased weight [9]. However, previ-
ous studies also demonstrated that metabolic health was 
the main determinant risk of acute myocardial infarction 
(MI) [1] or CV outcomes, not obesity itself [10].
The presence of coronary artery atherosclerosis is an 
established marker of future CV risk in symptomatic 
individuals [11]. However, the association of those find-
ings according to obesity and presence of MetS and their 
association with clinical outcomes has not been rigor-
ously studied. Thus, in the present study we sought to 
investigate the interplay of BMI, MetS and CAD detected 
by coronary computed tomography and their association 
with future CV events.
Methods
Study population
The methods of the Partners Healthcare CT Registry 
have been previously described [11, 12]. In brief, we 
included all consecutive subjects older than 18  years of 
age who underwent a contrast enhanced cardiac com-
puted tomography angiography (CTA) for the evalu-
ation of the coronary arteries at the Massachusetts 
General Hospital or the Brigham and Women’s Hospital 
from 2004–2011. All CTA scans were performed with 
64 detector or newer generation scanners. We excluded 
asymptomatic patients referred for screening purposes or 
research protocols and patients with prior known CAD 
[defined as prior percutaneous coronary intervention 
(PCI), coronary artery bypass graft surgery (CABG), or 
MI]. The Partners’ Healthcare Institution Review Board 
approved the study.
Coronary CTA exam acquisition and interpretation
Coronary CTA were conducted according to published 
guidelines [13, 14] and institutional protocols at the 
time of scan acquisition. CTA results were ordinally cat-
egorized as having no (0%), non-obstructive (<50%), or 
obstructive (≥50%) coronary artery disease (CAD). Ves-
sels less than 2 mm luminal diameter were not evaluated. 
We used the 18 segment coronary model proposed by 
the American Heart Association [14] to categorize CAD 
presence, extent, and severity for each segment. More 
detailed analysis of the extent and severity of CAD were 
performed using previously validated scores:
  • Segment involvement score (SIS): the sum of the 
number of segments with any plaque, which ranges 
from 0 to 17 [15].
  • Segment severity score (SSS): each segment receives 
a value according the amount of disease present in 
that vessel (0: no CAD, 1: non-obstructive CAD, 2: 
50–70% stenosis, 3:  >70% stenosis). The final score 
is the sum of each individual score, and ranges from 
zero to 51 [16].
Baseline risk factors
We reviewed all clinical data prior to the coronary CTA 
to verify the presence or absence of risk factors [17, 
18]. We defined hypertension using the most recent 
definition for components of metabolic syndrome, as 
a systolic blood pressure  ≥130  mmHg, diastolic blood 
pressure  ≥85  mmHg, or diagnosis/treatment of hyper-
tension. We defined obesity as body mass index ≥30 kg/
m2. We defined hypertriglyceridemia as triglycer-
ides  ≥150  mg/dL. We defined low high density lipo-
protein cholesterol (HDL) as  <40  mg/dL (male) or 
HDL  <50  mg/dL (women). We defined type 2 diabetes 
mellitus (T2DM) as a hemoglobin A1C (HbA1c) ≥6.5% 
(45 mmol/mol) [19], two fasting glucose levels ≥126 mg/
dL, or diagnosis/treatment of T2DM. We defined dys-
glycemia as HbA1C  ≥  5.7% (39  mmol/mol) and  <6.5% 
(45  mmol/mol) or fasting glucose level 100–125  mg/dL 
without known T2DM [19]. We categorized smoking as 
never, former, or current (tobacco within the last month). 
We defined family history of premature CAD as any first-
degree family member with clinical CAD prior to age 60.
For each patient, we determined the total number of 
cardiometabolic (CM) risk factors present, since clus-
tering of these common risk factors have been recog-
nized as the key contributors to the pathogenesis of both 
T2DM and cardiovascular disease [20, 21]. We used the 
following CM risk factors: (1) obesity; (2) low HDL; (3) 
hypertriglyceridemia; (4) hypertension; and, (5) dysgly-
cemia. All patients were verified as having T2DM or not 
according to the criteria listed above. BMI was used as 
a measure of central adiposity (instead of waist circum-
ference), although these two measures have consistently 
been shown to be highly correlated [22] and have similar 
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predictive value for future onset of diabetes [23] or clini-
cal CV disease [24]. This method is consistent with the 
recommendations of the American Association of Clini-
cal Endocrinologists [25] and the World Health Organi-
zation [26], both of which include BMI as a means of 
defining CM risk.
Cardiovascular outcomes
Two cardiologists blinded to CTA results reviewed all 
patient medical records for adjudication of cardiovas-
cular events. We mailed a standardized questionnaire 
to each patient in order to ensure that events outside of 
our healthcare network were captured. For patients who 
did not return the questionnaire after repeated mail-
ings, we conducted scripted phone interviews. In addi-
tion, patients had the option of completing a web-based 
version of the questionnaire via the REDCap (Research 
Electronic Data Capture) system [27], which is secure, 
encrypted, and HIPAA compliant. Two cardiologists 
blinded to CTA results verified each self-reported event 
via outside medical record review. Discrepancies were 
adjudicated by consensus.
We defined major adverse cardiovascular events 
(MACE) as a composite of non-fatal myocardial infarc-
tion, late coronary revascularization (>90 days), recurrent 
unstable angina requiring emergency or inpatient hospi-
tal evaluation, and cardiovascular death. We addition-
ally evaluated the outcome of cardiovascular death and 
non-fatal MI to avoid inherent bias of softer outcomes 
(e.g. angina, coronary revascularization). Diagnosis of MI 
was confirmed by two of three: chest pain or equivalent 
symptom complex; positive cardiac biomarkers; ECG 
changes typical of MI [28]. Time to the first coronary 
revascularization procedure (PCI or CABG) was evalu-
ated. Early revascularizations (≤90  days post coronary 
CTA) were removed from survival analysis to minimize 
verification bias [29–31]. That is, patients with ≥50% ste-
nosis by coronary CTA more frequently undergo inva-
sive angiography and revascularization early after the 
coronary CTA, whereas symptom driven late coronary 
revascularizations are less likely to be associated with 
the coronary CTA and more associated with CAD pro-
gression and prognosis. Unstable angina without revas-
cularization (USA) was defined as chest pain or chest 
pain equivalent with dynamic electrocardiogram (ECG) 
changes such as ST depression or T wave inversion but 
without abnormal cardiac biomarkers and characterized 
by: (1) rest symptoms; (2) new onset angina (less than 
2 months duration); or, (3) increasing duration or severity 
of previously stable anginal symptoms [32].
We confirmed all deaths using the Social Security 
Death Index. For all patients who died, the cause of death 
was obtained using the National Death Index as well as 
the Massachusetts Department of Vital Statistics, when 
applicable. In addition, other relevant clinical records 
(e.g. death notes, autopsy findings, hospice notes) related 
to death were reviewed. Using all available data, two car-
diologists blinded to the CTA results adjudicated cause 
of death, with cardiovascular death defined as a primary 
cause of acute MI, atherosclerotic coronary vascular 
disease, congestive heart failure, valvular heart disease, 
arrhythmic heart disease, stroke, or other structural or 
primary cardiac cause of death.
Statistical analysis
Continuous variables are reported as mean and standard 
deviation. Categorical variables are reported as counts 
and proportions. Continuous variables were compared 
between groups using analysis of variance techniques. 
Median segment scores were compared between groups 
using the Kruskal–Wallis test. Categorical variables were 
compared using Chi squared test or Fisher’s exact test, 
where appropriate. The Kaplan–Meier method and log 
rank test were used to assess event-free survival for all 
outcomes of interest. Univariable and multivariable Cox 
proportional hazards models were constructed to com-
pare risk between strata. The assumption of proportional 
hazards was tested by the scaled and unscaled Schoenfeld 
residuals and resulted in non-significant findings in in all 
analyses. In order to maximize statistical power of the 
BMI analysis, we further evaluated the full range of BMI 
as a non-linear J-shaped curve using a second degree 
multivariable fractional polynomial method [33]. Frac-
tional polynomials allow for nonlinear modeling through 
selection of transformation powers of independent vari-
ables that allow for the most parsimonious best model 
fit. We used the FRACPOLY command in Stata version 
12.1 (Statacorp, College Station, TX, USA). We evalu-
ated for interactions between the transformed BMI and 
MetS in the fully adjusted Cox regression model. Hoch-
berg or Holm’s corrections for multiple comparisons 




3884 patients underwent CTA during the study period, 
with 773 having no BMI data, 10 had incomplete clini-
cal outcomes data, 117 had prior CAD, 20 had did not 
have fully evaluable CTA, and 1846 were lacking risk 
factor data to define smoking status or MetS. Therefore, 
the study population consisted of 1118 individuals who 
met all inclusion criteria and had complete baseline and 
follow-up data.
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Baseline characteristics
As noted on Table 1, the study population was predomi-
nantly male (58%) with a mean BMI of 30 ± 7 kg/m2 and 
increasing prevalence of baseline cardiovascular risk 
factors with increasing BMI. 133 (22%) subjects with-
out MetS met criteria for T2DM and 318 (63%) subjects 
with MetS met criteria for T2DM. BMI was categorized 
as  <20  kg/m2 (n  =  22, 2%), 20–24.9  kg/m2 (n  =  206, 
18%), 25–29.9 kg/m2 (n = 423, 38%), 30–39.9 (n = 372, 
33%), and >40 kg/m2 (n = 95, 8%). Age and smoking did 
not correlate directly with BMI, although those with 
BMI > 40 kg/m2 were more likely to be current smokers 
(17 versus 11% overall) and those with BMI < 20 kg/m2 
were less likely (5 versus 11% overall).
During a median 3.2 (IQR 1.9–4.5) years follow-up, 
there were 46 (4.1%) all-cause deaths, 21 (1.9%) cardio-
vascular deaths, 13 (1.2%) non-fatal MI, 13 (1.2%) unsta-
ble angina without revascularization, and 34 (3.1%) late 
coronary revascularizations.
Prevalence, extent, and severity of CAD more 
strongly associated with metabolic syndrome rather 
than increasing BMI
By univariable analysis, BMI was associated with pres-
ence, extent, and severity of CAD. The univariable odds 
ratios for each 1 kg/m2 increase in BMI as a continuous 
variable (excluding <20 kg/m2) for any CAD, obstructive 
CAD, extensive CAD, SIS, and SSS were 1.03 (1.01–1.05, 
p  =  0.012), 1.01 (0.99–1.03, p  =  0.3), 1.02 (1.0–1.04, 
p = 0.058), 1.03 (1.01–1.05, p = 0.012), 1.03 (1.01–1.05, 
p  =  0.012), respectively. However, in multivariable 
analysis after adjustment for age, gender, smoking and 
each individual metabolic syndrome component, these 
values were not significant at 1.03 (1.0–1.05, p =  0.06), 
1.0 (0.98–1.03, p =  0.8), 1.01 (0.99–1.04, p =  0.2), 1.03 
(0.99–1.05, p = 0.06), 1.03 (0.99–1.05, p = 0.06), respec-
tively, suggesting that BMI served as a marker for the 
components of MetS, which was more significantly asso-
ciated with CAD than BMI. Each incremental increase 
in BMI was associated with increasing likelihood of 
MetS (OR 1.28 per 1  kg/m2, p  <  0.001). Within each 
BMI category, when compared to those who were meta-
bolically healthy (−MetS), those who were metabolically 
unhealthy (+MetS) had greater extent of CAD (Fig. 1).
Prognosis more strongly associated with metabolic 
syndrome rather than increasing BMI
By univariable linear analysis, BMI (excluding 
BMI  <  20  kg/m2) was not associated with CV MACE, 
HR  =  1.26 (0.99–1.06, p  =  0.13) per each 1  kg/
m2 increase in BMI. Obesity as a binary variable 
(BMI ≥ 30 kg/m2.) was not associated with CV MACE, 
HR = 1.28 (0.79–2.05, p = 0.31). MetS as a binary vari-
able was associated with CV MACE, HR =  2.09 (1.28–
3.40, p = 0.003).
Within each BMI category, prognosis was poorer for 
those who were metabolically unhealthy (+MetS) versus 
healthy as indicated by increased annualized incidence of 
adverse CV events (Fig. 2). Univariable and multivariable 
(adjusted for age, gender and smoking) HR for each BMI 
category are presented on Table  2 for the endpoint of 
CV MACE (top panel) and CV death/MI (Table 2, lower 
Table 1 Baseline characteristics
BMI body mass index, CAD coronary artery disease, CCTA coronary CT angiography, HDL high-density lipoprotein cholesterol, SIS segment involvement score, TG 
triglycerides
BMI (kg/m2) <20 20–24.9 25–29.9 30–39.9 >40 All p value
n 22 206 423 372 95 1118
Age 56 ± 15 57 ± 14 57 ± 13 56 ± 13 54 ± 12 57 ± 13 0.23
Male 5 (23%) 97 (47%) 279 (66%) 216 (58%) 49 (52%) 648 (58%) <0.0001
Hypertension 7 (32%) 87 (42%) 212 (50%) 249 (67%) 76 (80%) 626 (56%) <0.0001
Dysglycemia 15 (68%) 119 (58%) 271 (64%) 283 (76%) 79 (83%) 760 (68%) <0.0001
Diabetes 8 (36%) 55 (27%) 140 (33%) 192 (52%) 56 (59%) 451 (40%) <0.001
Elevated TG 3 (14%) 33 (16%) 110 (26%) 145 (39%) 42 (44%) 335 (30%) <0.0001
Low HDL 9 (41%) 37 (18%) 127 (30%) 182 (49%) 58 (61%) 414 (37%) <0.0001
Metabolic syndrome 4 (18%) 28 (14%) 98 (23%) 286 (77%) 86 (91%) 372 (33%) <0.001
Current smoker 1 (5%) 25 (12%) 42 (10%) 37 (10%) 16 (17%) 123 (11%) 0.19
Family history 4 (20%) 91 (44%) 195 (46%) 156 (42%) 35 (37%) 481 (43%) <0.001
CCTA results <0.0001
No CAD 11 (50%) 103 (50%) 157 (37%) 138 (37%) 28 (29%) 436 (39%)
<50% 9 (41%) 72 (35%) 157 (37%) 145 (39%) 45 (47%) 425 (38%)
>50% 2 (9%) 31 (15%) 110 (26%) 89 (24%) 22 (23%) 257 (23%)
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panel), although this endpoint included just 31 events 
and thus was underpowered for stratification by BMI 
categories.
To evaluate the full range of BMI as a non-linear 
J-shaped curve, we first evaluated BMI as a predictor 
of CV MACE in a univariable second degree fractional 
polynomial model (Fig.  3, top left). The best fit model 
included BMI−1 and BMI3, with HR  =  182 (2–15675, 
p = 0.02) and HR = 1.02 (1.001–1.03, p < 0.001), respec-
tively. We then adjusted for age, gender, and current 
smoking (Fig.  3, top right). The best fit model included 
BMI−2 and BMI3, with HR = 1395 (6–313,075, p = 0.009) 
and HR = 1.02 (1.01–1.03, p < 0.001), respectively. After 
stratification by MetS, we modeled those without MetS 
by adjusting first by BMI, age, gender, and smoking 
and then incrementally evaluating each of the indi-
vidual components of MetS (low HDL, hypertension, 
dysglycemia, elevated TG) for significance. The best fit 
model included BMI2, BMI3, age, gender, current smok-
ing, and hypertension (Figure  3, bottom left), with HR 
for BMI  =  0.42 (0.21–0.82, p  =  0.01) and HR  =  1.19 
(1.05–1.34, p  =  0.008), respectively. Last, we modeled 
those with MetS and adjusted for age, gender and cur-
rent smoking (Fig.  3, bottom right). The best fit model 
included BMI3, BMI3, age, gender, and current smok-
ing, with HR for BMI = 0.93 (0.85–1.01, p = 0.095) and 
HR = 1.05 (1.0–1.10, p = 0.05), respectively. The cumula-
tive incidence of CV MACE for those with and without 
MetS could be further stratified according to CTA find-
ing, as demonstrated in Fig. 4.
In order to evaluate for other relationship of BMI with 
MetS, we included in the fractional polynomial Cox 
regression model a test for interaction between BMI and 
MetS that was not significant in all analyses, indicating 
no additional influence of BMI upon MetS as a predictor 
of CV MACE.
Discussion
Our study has demonstrated that metabolic risk modi-
fies the association of BMI with increasing prevalence, 
extent, and severity of CAD. Metabolic risk among BMI 
categories also modified the risk of incident cardiovas-
cular events. These findings suggest that although BMI 
serves as a marker of CAD risk when considered in iso-
lation, the hazard associated with BMI is mostly medi-
ated by the presence of other metabolic risk factors. 
Our group has previously demonstrated an incremen-
tal increase in CAD burden and future adverse events 
with incrementally worse metabolic health [7]; the cur-
rent study extends upon the prior analysis by modeling 
CV prognosis non-linearly across the full range of BMI. 
Although most obese individuals have a cluster of CM 
risk factors, those without this pattern have a signifi-
cantly lower probability of CAD and future CV events. 
Therefore, one must carefully evaluate all potential risk 
factors when considering the presence or absence of an 
“obesity paradox” since not all obesity phenotypes have a 
homogenous prevalence of CAD or risk of adverse CHD 
events.
In prior studies, a variety of authors have suggested 
evidence of an “obesity paradox,” yet others have dis-
credited this finding as an effect of residual confounding. 
For example, Lavie et al. [3] have noted that since heart 
failure is a catabolic state, obese patients have improved 
survival relative to normal weight, which may simply 
demonstrate residual confounding due to more advanced 
disease state. Similar findings of “obesity paradox” have 
been reported with hypertensive patients, although this 
Fig. 1 Odds of extensive CAD (Segment Involvement Score, SIS > 4), 
according to MetS and BMI. CAD coronary artery disease, MetS meta-
bolic syndrome, BMI body mass index, kg/m2
Fig. 2 Absolute annualized adverse CV events demonstrated a 
J-shaped curve according to BMI (inset). The presence of MetS (dark 
bar) predicted worse outcomes within the BMI range of 20–39.9 kg/
m2. CV cardiovascular, MetS metabolic syndrome, BMI body mass 
index, kg/m2
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Table 2 Univariable and multivariable hazard ratios for cardiovascular major adverse events (top panel Cardiovascular 
MACE) and the combined events of cardiovascular death or MI (lower rows CV Death or MI)
Multivariable models were further adjusted for age, gender, and current smoking. BMI body mass index, CV cardiovascular, HR hazard ratio, MetS metabolic syndrome, 
MI myocardial infarction
Predictor Univariable Multivariable
Variable HR 95% CI p value HR 95% CI p value
Cardiovascular MACE (CV death, non-fatal MI, late coronary revascularization, and unstable angina)
 BMI, kg/m2 1.03 0.99–1.06 0.13 1.04 1.01–1.08 0.02
 Obesity 1.28 0.79–2.05 0.31 1.45 0.9–2.34 0.13
 MetS 2.09 1.28–3.4 0.003 1.88 1.15–3.08 0.01
 BMI 20-24.9, MetS− 1 Reference 1 Reference
 BMI 20-24.9, MetS+ 1.67 0.47–5.93 0.43 1.52 0.43–5.39 0.52
 BMI 25-29.9, MetS− 0.5 0.22–1.14 0.1 0.51 0.22–1.17 0.11
 BMI 25-29.9, MetS+ 1.56 0.65–3.7 0.32 1.12 0.47–2.69 0.8
 BMI 30-39.9, MetS− 0.31 0.07–1.41 0.13 0.38 0.08–1.74 0.21
 BMI 30-39.9, MetS+ 1.13 0.56–2.3 0.73 1.15 0.56–2.33 0.71
CV death or MI
 BMI, kg/m2 1.01 0.96–1.06 0.7 1.03 0.98–1.09 0.25
 Obesity 1.44 0.71–2.91 0.31 1.81 0.88–3.71 0.11
 MetS 2.61 1.23–5.55 0.01 2.19 1.02–4.67 0.04
Fig. 3 Log hazard ratio according to body mass index (kg/m2) for cardiovascular adverse events (cardiovascular death, nonfatal MI, unstable 
angina requiring hospitalization, or coronary revascularization >90 days post-CTA). HR are unadjusted (top left), adjusted for all patients (top right) 
and adjusted and stratified by absence (bottom left panel) or presence (bottom right panel) of metabolic syndrome (MetS). Reference BMI was set at 
20 kg/m2. An “obesity paradox,” where patients with relatively increased BMI from 20–40 kg/m2 had lower hazard of adverse CV events was observed 
particularly in the subjects without MetS, which may indicate residual confounding
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may relate to different pathophysiology and co-mor-
bid conditions among the obese versus normal weight 
with hypertension [3]. Despite such counter-intuitive 
reports, a large pooled analysis of 19 prospective studies 
that excluded smokers and those with known cancer or 
heart disease identified no evidence of obesity paradox 
[34]. In this study, a J-shaped curve for obesity in asso-
ciation with all-cause death was noted and the healthiest 
BMI was noted to be 20–24.9 kg/m2. Each incremental 5 
point increase in BMI was associated with a hazard ratio 
of 1.31 (95% CI, 1.29–1.33) [34]. Similarly, the Prospec-
tive Studies Collaboration identified the healthiest BMI 
as 22–25  kg/m2 for the lowest association with cardio-
vascular death with a hazard ratio per 5 point increase of 
1.32 (95% CI, 1.29–1.36) [35]. An important large study 
of 13,874 patients undergoing coronary CTA reported 
greater prevalence, extent and severity of CAD in over-
weight and obese individuals. BMI was independently 
associated with a higher risk of non-fatal MI. Although 
BMI was not associated independently with all-cause 
death, this study was limited by linear modeling of BMI 
as a risk factor without consideration of modeling effects 
of extreme BMI < 20 kg/m2 or BMI > 40 kg/m2 [36].
An emerging phenotype of “metabolically healthy obe-
sity (MHO)” has been recognized, although the literature 
to date is not comprehensive. A recent systematic review 
on the topic of metabolically healthy obesity identified 15 
cohort and 5 cross-sectional studies that defined meta-
bolically healthy obesity using either lack of insulin resist-
ance or lack of MetS [37]. This review noted that only 
two of seven cohort studies that evaluated all-cause death 
found a significantly increased risk, one of seven evalu-
ating CV deaths, and 3 of 9 evaluating incident CVD. 
However, 5 of 9 evaluating incident CVD demonstrated 
a consistent trend for MHO to have an increased clini-
cal risk relative to metabolically healthy normal weight, 
while only 1 of 9 studies showed no association whatso-
ever. Thus, although the available studies to date are not 
numerous, the majority of cohort studies published have 
not consistently proven that metabolically healthy obe-
sity is not associated with increased adverse clinical out-
comes when compared to metabolically healthy normal 
weight individuals (in contrast to metabolically unhealthy 
obesity which does convey worse prognosis). However, 5 
cross-sectional studies suggested a slight increase in sub-
clinical atherosclerosis among those with MHO, which 
suggests that with a longer follow-up and larger sample 
Fig. 4 Cumulative incidence of adverse cardiovascular (CV) events (CV death, nonfatal MI, unstable angina requiring hospitalization, or coronary 
revascularization >90 days post-CTA), stratified by no MetS (left panel) and MetS (right panel) and normal CTA versus non-obstructive CAD (short 
dash line) versus obstructive CAD (long dash). Overall, patients with MetS experienced outcomes over 2× the rate of those without. Those with 
MetS and obstructive CAD experienced very high adverse events. The left panel was adjusted as in Fig. 3 for BMI, age, gender, current smoking, and 
hypertension. The right panel was adjusted as in Fig. 3 for BMI, age, gender, and current hypertension
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size a small increased risk might be identified even for 
metabolically healthy obesity. A study looking at progres-
sion of plaque with coronary CTA reported that MetS 
was an independent predictor of progression of coronary 
artery stenosis or development of vulnerable plaque after 
accounting for traditional CM risk factors including BMI, 
HR = 1.47, (95% CI 1.01–2.15, p = 0.045) [38].
Scientists have debated the relative merits of regional 
adiposity (e.g., abdominal or central obesity) versus abso-
lute weight metrics, such as body mass index. Although 
most widely applied criteria for MetS diagnosis place 
greater emphasis on central adiposity, this measure is 
rarely measured clinically and thus the WHO and oth-
ers [25, 26], often substitute BMI as a reasonable, albeit 
imperfect, surrogate. Nevertheless, several studies have 
demonstrated a relevance of central adiposity. For exam-
ple, a large screening cross-sectional study of 21,335 mid-
dle-aged Korean men identified that abdominal adiposity 
was associated with CAC, although ultrasound evidence 
of non-alcoholic fatty liver disease when compared to 
abdominal obesity, demonstrated an even stronger asso-
ciation for CAC [39]. On the other hand, in a smaller 
Asian screening cross-sectional study of 3157 subjects 
who underwent CT, visceral adiposity was associated 
with CAD in univariable analysis but not by multivariable 
analysis after adjustment for age, gender, dyslipidemia, 
diabetes mellitus, and the ratio of visceral to subcuta-
neous fat [40]. Yet another interesting study stratified 
2078 normal weight subjects (18.5  ≤  BMI  <  25  kg/m2) 
who underwent CTA according to percentage of body 
fat. Individuals with the highest tertile of body fat, even 
at normal weight (“normal weight obesity”) exhibited 
increased prevalence of CTA non-calcified coronary 
plaques (21.6 vs. 14.5%, p = 0.039), more abnormal aortic 
pulse wave velocity, and increasingly abnormal cardio-
metabolic risk factors [41]. Thus, although not routinely 
measured in most clinics, several reports have demon-
strated a value of evaluating central adiposity.
Currently over half of American adults are overweight 
or obese. Furthermore, in contrast to previous decades 
there is a shift toward a greater proportion of morbid 
versus milder obesity [3]. Some encouraging recent data 
suggest a plateau in the prevalence of American obesity, 
yet the prevalence worldwide has continued to increase 
in almost every corner of the globe, with certain regions 
particularly afflicted, such as parts of India [42]. For 
example, the worldwide prevalence of obesity has dou-
bled from 1980 to 2008, such that over 1.4 billion adults 
are now overweight and a 0.5 billion are obese. Even 
more concerning is the crisis of childhood obesity with 
43 million preschoolers [43] worldwide overweight, who 
may begin to have adverse cardiovascular structural and 
metabolic effects even in childhood and early teen years 
[44]. Obese individuals are at increased risk of diabetes, 
heart disease, stroke, sleep apnea, and other chronic con-
ditions and consume increased healthcare resources rela-
tive to those of normal weight.
In spite of the debate about an “obesity paradox,” this 
often represents a comparison to unhealthy thinner 
patients in an end-stage disease state (as in CHF), resid-
ual confounding (such as when smoking is not adequately 
accounted for), or overly adjusting for co-linear variables 
associated with obesity (such as dyslipidemia, dysglyce-
mia, or hypertension). Because of the important health 
effects of obesity as demonstrated by our study and oth-
ers, for conditions including CAD, obstructive sleep 
apnea, heart failure, stroke, or death, successful weight 
loss interventions are of great importance. Although 
guidelines endorse exercise and healthy as first line rec-
ommendations, long term success through lifestyle inter-
ventions remain elusive for many patients. Recently, the 
3  year follow-up results of the STAMPEDE trial, which 
compared bariatric surgery to non-surgical intervention 
for obese patients with uncontrolled type 2 diabetes mel-
litus and noted persisting improvements in metabolic 
health and weight loss after for surgery [45]. Thus, iden-
tifying patients with MetS, which may be treatable and in 
some cases reversible through lifestyle or surgical inter-
vention, could benefit lifetime cardiovascular risk.
Contemporary interest to improve risk stratifica-
tion of patients with either MetS or diabetes mellitus 
have led to limited studies of screening populations. For 
example, although major guidelines define diabetes mel-
litus as high-risk for CAD events, one study screened 98 
asymptomatic patients with diabetes using CAC, CTA, 
and carotid ultrasound and identified 55 (56%) who had 
no detectable CAD and could potentially be re-classified 
from high to low CV risk. Sixteen subjects (including 
three with CAC = 0) were found to have obstructive CAD 
by CTA, but no clinical outcomes were reported for this 
cross-sectional study [46]. Similarly, Ryu et  al. screened 
755 patients with MetS by CTA and identified an increas-
ing extent and burden of CAD according to the number 
of MetS risk factors, among which abdominal obesity 
and hypertension had the strongest effect [47]. A small 
study of 39 Japanese men also noted that those with ver-
sus without MetS had higher prevalence of CAD (31.3 
versus 4.3%, p  =  0.033) and lower serum adiponectin 
levels (4.5 ± 0.6 versus 6.4 ± 0.6 μg/mL, p = 0.014) [48]. 
Another study that screened 1000 asymptomatic Korean 
patients with diabetes found that 78% had no detectable 
CAD by CTA. Although 22% had some plaque that may 
modify preventive clinical decision making, the inci-
dence of downstream adverse clinical events was low over 
17  months follow-up and consisted entirely of 1 unsta-
ble angina and 14 coronary revascularizations [49]. The 
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FACTOR-64 study, which randomized asymptomatic dia-
betics to screening by CTA or standard therapy also failed 
to show any significant difference in downstream events, 
owing to the unexpectedly low number of events and the 
use of preventive therapies in both arms (>70% on statins) 
[50]. Thus, although screening can further characterize 
the otherwise homogenous risk categorization of patients 
with diabetes from simply “high risk,” the impact of such 
testing upon the otherwise low clinical event incidence 
among asymptomatic patients remains uncertain.
Notwithstanding these results, our study must be inter-
preted in the context of its inherent limitations. First, a 
retrospective design in a tertiary referral center may 
result in selection bias. Similarly, the patients were clini-
cally referred for a coronary CTA, which may increase 
the prevalence of CAD, and clinical risk compared to the 
general population. Also, we did not have available meas-
ures of central adiposity, such as waist circumference. In 
spite of these limitations, we demonstrate that although 
obesity is associated with CAD prevalence, extent, sever-
ity and prognosis much of the risk can be explained by 
cardiometabolic health within obesity subcategories.
Conclusion
Compared to individuals with normal BMI (20–24.9 kg/
m2), there was an increased prevalence, extent, and 
severity of CAD for those with BMI > 25 kg/m2. BMI by 
univariable analysis demonstrated a J-shaped curve with 
prognosis, though this association was significantly mod-
ified after adjusting for metabolic risk factors. BMI was 
a marker for MetS, which was more significantly associ-
ated with prognosis.
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